Genetic biomarkers for fluorouracil toxicity prediction: The long road to clinical utility

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 989-990

  Lee, Adam M ^a   Diasio, Robert B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG DERIVATIVE; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COLORECTAL CANCER; EDITORIAL; GENE LINKAGE DISEQUILIBRIUM; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; VARIABLE NUMBER OF TANDEM REPEAT; COLORECTAL TUMOR; GENETICS; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; THYMIDYLATE SYNTHASE;

EID: 84901635863     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.4479     Document Type: Editorial

References (19)

1. Rosmarin D, Palles C, Church D, et al: Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systemic review, and meta-analysis. J Clin Oncol 32:1031-1039, 2014
2. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, et al: Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 14:1-6, 1995
3. Wei X, McLeod HL, McMurrough J, et al: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:610-615, 1996 (Pubitemid 26349163)
4. Vreken P, Van Kuilenburg AB, Meinsma R, et al: A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherited Metabolic Dis 19:645-654, 1996 (Pubitemid 26315916)
5. Morel A, Boisdron-Celle M, Fey L, et al: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895-2904, 2006 (Pubitemid 44849017)
6. Schwab M, Zanger UM, Marx C, et al: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26:2131-2138, 2008
7. Gross E, Busse B, Riemenschneider M, et al: Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 3:e4003, 2008
8. Amstutz U, Farese S, Aebi S, et al: Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment. Pharmacogenomics 10:931-944, 2009
9. Alberts SR, Sargent DJ, Nair S, Mahoney MR, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383-1393, 2012
10. Lee A, Shi Q, Pavey ES, et al: Validation of DPYD variants DPYD*2A, I560S and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. J Clin Oncol 31:207s, 2013 (suppl; abstr 3510)
11. The 1000 Genomes Project Consortium, Abecasis GR, Auton A, et al: An integrated map of genetic variation from 1,092 human genomes. Nature 491:56-65, 2012
12. National Center for Biotechnology Information: Database of single nucleotide polymorphisms (dbSNP). (dbSNP Build ID: Human 137). www.ncbi.nlm.nih.gov/SNP/
13. Vreken P, Van Kuilenburg AB, Meinsma R, et al: Identification of novel point mutations C29R, R886H, and R235W. Hum Genet 101:333-338, 1997
14. Offer SM, Wegner NJ, Fossum C, et al: Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 73:1958-1968, 2013
15. Offer SM, Lee AM, Mattison LK, et al: A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther 94:158-166, 2013
16. Saif MW, Lee AM, Offer SM, et al: A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxicity: Potential for an individualized medicine approach. Mayo Clin Proc (in press)
17. Zaanan A, Dumont LM, Loriot MA, et al: A case of 5-FU related severe toxicity associated to the p.Y186C DPYD variant. Clin Pharmacol Ther 2013 [epub ahead of print on September 13, 2013]
18. US Food and Drug Administration: Table of pharmacogenomic biomarkers in drug labels. www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm
19. Caudle KE, Thorn CF, Klein TE, et al: Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther [epub ahead of print on August 29, 2013]